An “Outside-In” and “Inside-Out” Consideration of Complement in the Multiple Sclerosis Brain: Lessons From Development and Neurodegenerative Diseases

B. Paul Morgan 1, Jennifer L. Gommerman 2 and Valeria Ramaglia 2*

1 UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, United Kingdom, 2 Department of Immunology, University of Toronto, Toronto, ON, Canada

The last 15 years have seen an explosion of new findings on the role of complement, a major arm of the immune system, in the central nervous system (CNS) compartment including contributions to cell migration, elimination of synapse during development, aberrant synapse pruning in neurologic disorders, damage to nerve cells in autoimmune diseases, and traumatic injury. Activation of the complement system in multiple sclerosis (MS) is typically thought to occur as part of a primary (auto)immune response from the periphery (the outside) against CNS antigens (the inside). However, evidence of local complement production from CNS-resident cells, intracellular complement functions, and the more recently discovered role of early complement components in shaping synaptic circuits in the absence of inflammation opens up the possibility that complement-related sequelae may start and finish within the brain itself. In this review, the complement system will be introduced, followed by evidence that implicates complement in shaping the developing, adult, and normal aging CNS as well as its contribution to pathology in neurodegenerative conditions. Discussion of data supporting “outside-in” vs. “inside-out” roles of complement in MS will be presented, concluded by thoughts on potential approaches to therapies targeting specific elements of the complement system.

Keywords: complement, multiple sclerosis, pathology, outside-in, inside-out

INTRODUCTION

Multiple sclerosis (MS) is traditionally considered to be a chronic immune-mediated demyelinating disease of the central nervous system (CNS) mediated by autoreactive lymphocytes that are primed against a CNS antigen in the periphery, enter the CNS via breached blood-brain barriers (BBB), and are reactivated in the perivascular spaces of postcapillary venules and meningeal vessels (Engelhardt et al., 2016). As such, one could think of MS as a disease mediated by “outside-in” mechanisms, where the peripheral immune system from the “outside” enters the “inside” of the brain causing injury. Indeed, currently approved disease-modifying treatments (DMT),
which are effective in modulating peripheral immunity, reduce demyelinating lesions in relapsing-remitting MS (RRMS). The “outside-in” hypothesis also finds support in genome-wide association studies that identified immune-related susceptibility gene variants in a large cohort of MS patients (International Multiple Sclerosis Genetics Consortium, 2019).

An alternative theory that argues against a causal role of immune cells in the initiation of MS proposes that a primary “cytodegeneration” in the CNS, originating at oligodendrocytes and/or neurons, starts years before the manifestation of any clinical symptoms. In susceptible individuals, this CNS-intrinsic cytodegeneration is followed by an autoimmune inflammatory reaction against antigens that are shed as a result of the primary cellular damage (Stys et al., 2012b). This alternative hypothesis centered on “inside-out” disease mechanisms, finds support in ultrastructural evidence of earliest myelin changes identified in the layer of the myelin sheath that is nearest the axon (Rodriguez and Scheithauer, 1994), in pathological evidence of myelin and axonal degeneration that is not accompanied by evidence of an adaptive immune response in the normal-appearing white matter (Trapp et al., 1998; Henderson et al., 2009), and in clinical evidence of the inability to stop disease progression using immunomodulatory drugs (reviewed in Ciotti and Cross, 2018).

Overall, while inflammatory processes are detected in the CNS of MS patients both at the early and late disease stages (Frischer et al., 2009; Machado-Santos et al., 2018; Fransen et al., 2020) and are undoubtedly important in shaping pathological processes, the evidence is equally consistent with either primary autoimmune pathogenesis of MS (“outside-in” hypothesis) or a model in which an initial injury causes shedding of a high level of autoantigens, which in turn triggers a secondary inflammatory reaction (“inside-out” hypothesis). Therefore, the question remains: is MS initiated by “outside-in” or “inside out” disease mechanisms?

One piece of the puzzle is the complement system, a major arm of the innate immune system that has been implicated in the pathogenesis of MS since the early 1970s (Lumsden, 1971). While it is widely assumed that, in MS, complement proteins derived from the circulation enter the brain parenchyma through a leaky BBB to tag antigen-antibody complexes (“outside-in” paradigm), a potential role of CNS-derived complement components in MS disease processes that originate within the CNS (“inside-out” paradigm) has been largely ignored. This review focuses on how the complement proteins can shape the MS-affected CNS.

THE COMPLEMENT SYSTEM

Complement plays a central role in the innate immune system. It consists of approximately 50 fluid-phase and cell surface-associated proteins that provide the first line of defense against pathogens and clear immune complexes by tagging and mediating removal of non-self (i.e., pathogens) or altered-self (i.e., dead and dying cells) antigens (Ricklin et al., 2010). Detailed schematics of components and activation products of the complement cascade have been previously published including recently (Morgan and Harris, 2015; Carpanini et al., 2019), and are also shown in Figure 1. The complement system is activated via three initiating pathways (classical, alternative, and lectin). Regardless of the initiating pathway, complement activation converges on a common effector pathway, terminating in the formation of the terminal complement complex (TCC) that, in the context of cell membranes, creates a transmembrane pore, the membrane attack complex (MAC). The classical pathway is activated by binding of C1q, a component of the C1 complex, to the Fc domain of antibodies bound to antigens or directly to “danger” epitopes. The lectin pathway is initiated by the binding of mannose-binding lectin to certain carbohydrates expressed on the pathogen surface, whereas the alternative pathway is a powerful amplification loop initiated either spontaneously by low-rate hydrolysis of C3 or by C3b generated in the classical/lectin pathways and progresses through binding of activated factor B and generation of a C3-cleaving enzyme (convertase) on surfaces that lack complement inhibitors (Ricklin et al., 2010).

Regardless of the pathway of activation, complement acts through the production of opsonins (C3b, iC3b, C4b, etcetera) which are molecules that enhance the ability of macrophages and neutrophils expressing complement receptors to phagocytose material; anaphylatoxins (C3a, C5a) which are peptides that induce local and systemic inflammatory responses, increasing the permeability of blood vessels and attracting neutrophils through their chemotactic properties; and through direct killing of organisms by the MAC, which disrupts and forms pores in the phospholipid bilayer of a target cell (Ricklin et al., 2010).

While complement components exert their effector functions against “danger” signals on pathogens, healthy self tissue is protected from undesired complement activation by complement inhibitors present either in the fluid-phase or on membrane surfaces (Hajishengallis et al., 2017). Key complement regulators are indicated in Figure 1. A tight balance between activation and regulation keeps complement in check, whereas disruption of this balance caused by over-activation and/or insufficient regulation can result in tissue injury (Ricklin and Lambris, 2013).

SOURCES OF COMPLEMENT PROTEINS

Although complement components in plasma are synthesized mainly by hepatocytes in the liver, the discovery that CNS-resident cells such as glial cells and neurons can produce complement proteins (Levi-Strauss and Mallat, 1987; Morgan and Gasque, 1997; Gasque et al., 2000), was a prelude to the changing view of immune privilege in the CNS (Engelhardt and Coisne, 2011). For example, it is now appreciated that specialized pockets in the brain are not immune privileged. In particular, the dura that lies above the leptomeninges is transversed by functional lymphatics and fenestrated vasculature that lacks tight junctions, making it highly permeable to peripheral immune cells and soluble molecules (including complement proteins) that enter into the dura, even at a steady-state (reviewed in Rua and McGavern, 2018; Ramaglia et al., in press b). Therefore, in addition to a parenchymal source of complement, serum-derived...
FIGURE 1 | Activation and regulation of the complement (C) system. Recognition of target epitopes by C1q (Classical pathway) or MBL (Lectin pathway) result in the cleavage of C4 and formation of the C3 convertase, cleaving C3. C3 is also activated via the alternative pathway by a constant “tick-over” that can be amplified during pathological conditions. Cleaved C3 can nucleate the formation of the C5 convertase, cleaving C5 and eventually forming the terminal complement complex or membrane attack complex (TCC, MAC, C5b9), which can lyse membranes and/or induce cell activation. Activation of the complement system is tightly regulated by soluble (shown in italics) and membrane-bound proteins which can either inhibit the formation or accelerate the decay of the convertases or impede assembly of the C5b9 complex.

Abbreviations: C1INH, C1 inhibitor; C4bp, C4 binding protein; FI, factor I; MCP, membrane co-factor protein; CR1, complement receptor 1; DAF, decay-accelerating factor; FH, factor H; MBL, mannose-binding lectin.
Complement can enter the brain either through a leaky blood-brain barrier (BBB) and/or through a normally highly permeable meningeal brain barrier.

While little is known about the synthesis of terminal complement components in the brain (or whether this occurs at all), C1q and C3 synthesis in the brain has been studied in more detail. Astrocytes have been shown to produce C3 and Factor B, components of the alternative complement pathway, in vitro (Levi-Strauss and Mallat, 1987). Cultured human microglia were also shown to express C1q, C3, and C4 (Walker et al., 1995). Glioma cell lines have also been a useful tool to study complement biosynthesis by glial cells and have shown to be able to produce proteins of the complement alternative pathway, namely C3, factor B, factor H, and factor I (Gasque et al., 1992) and proteins of the classical complement pathway, namely C1q, C1r, C1s, C1-Inh, C2, C4, and C5 (Gasque et al., 1993). Astrocytes and microglia also express receptors for the complement activation products C3d and C3a (Gasque et al., 1996) and C5a (Gasque et al., 1995, 1997). In addition to glial cells, also neuronal cell lines can express complement components and regulators (i.e., C3, factor H (FH), factor B (FB), C4, C1-inhibitor (C1-inh), C1q, C5, C6, C7, and C9; Thomas et al., 2000). Early studies have also shown local production of complement proteins in the nervous system in vivo in response to peripheral nerve injury (Svensson and Aldskogius, 1992) or experimental lesions in the rat brain (Pasinetti et al., 1992).

More recent studies have shown that during the development of the visual system, synthesis of C1q is upregulated in neurons (Stevens et al., 2007). C1q mRNA and protein expression are also dramatically increased during normal aging of the mouse and human brain (Stephan et al., 2013; see “Early Complement Components in the Developing, Adult, and Normal Aging CNS” section). Using in situ hybridization, western blot, and immunohistochemical analysis of the myelinated and demyelinated MS hippocampus compared to controls, Michailidou and colleagues showed that C1q is synthesized also by hippocampal neurons and its expression increases intracellularly in neurons within MS tissue (Michailidou et al., 2015). A subsequent study showed that neuronal C1q synthesis, identified by in situ hybridization, occurs also in other areas of cortical gray matter in the MS brain (Watkins et al., 2016; see “Evidence Supporting the ‘Outside-In’ Paradigm” section). However, one study contradicting the concept that neurons represent an important source of C1q showed that microglial-specific deletion of C1q in mice results in lack of C1q in the adult brain while blood C1q levels remain unchanged, implicating microglia as the predominant CNS source of C1q (Fonseca et al., 2017).

In terms of C3, its synthesis has been reported in reactive astrocytes in MS and other neurodegenerative diseases, with C3 now being considered a marker for the designation of “A1” neurotoxic astrocytes (Liddelow et al., 2017). A1 astrocytes lose their ability to promote neuronal survival, outgrowth, and synaptogenesis, and instead induce the death of neurons and oligodendrocytes (Liddelow et al., 2017). Another study has shown neuronal synthesis of C3 in advanced MS cases. These C3-producing neurons were observed close to C3d⁺ microglial clusters at the edge of slowly expanding lesions (see “Evidence Supporting the ‘Inside-Out’ Paradigm” section; Michailidou et al., 2017). Altogether these data show that early complement components, particularly C1q and C3, are present in both the developing brain and normal aging brain independent of the breakdown of the blood-brain barrier, while the synthesis of complement proteins by neurons and glia is increased in the diseased brain, including in MS.

EARLY COMPLEMENT COMPONENTS IN THE DEVELOPING, ADULT, AND NORMAL AGING CNS

Stevens et al. (2007) were the first to demonstrate a substantial role for the upstream “early” classical complement pathway (C1q and C3) in eliminating redundant synapses during the development of the retinogeniculate system in the visual thalamus. In this system, extranumerary synapses are targeted by the complement component C1q, opsonized by C3 and phagocytosed by microglia via the complement receptor CR3 (Schafer et al., 2012), in a process which appears to be independent of the formation of the terminal “late” activation effector TCC/MAC (Figure 2A). This is supported by experimental studies in mice, in which deletion of C1q, C3 or CR3, or pharmacological (minocycline) disruption of microglia-mediated engulfment of synapses during early development leads to defects in eye-specific segregation of retinal ganglion cell projections (Stevens et al., 2007; Schafer et al., 2012). Therefore, the classical complement cascade is involved in mechanisms of synaptic refinement, similarly to what has been previously described for other molecules. These include pattern recognition molecules such as pentraxins (Bjartmar et al., 2006), the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2; Filippello et al., 2018), and the Class I Major Histocompatibility Complex. Involvement of the latter has been shown using mice in which deletion of two of the MHCI genes [H2-K(b) and H2-D(b)], impacts developmental refinement of retinogeniculate projections (Corriveau et al., 1998; Datwani et al., 2009).

During normal development, the complement components that participate in the pruning of synapses are likely produced locally in the brain since the BBB protects the CNS parenchyma from plasma-derived complement and immune cells. As mentioned, C1q can be expressed by microglia and certain neurons such as the retinal ganglion cells (RGC) in the visual system (Stevens et al., 2007). The cytokine transforming growth factor-β (TGF-β) has been identified as a factor secreted by astrocytes that is necessary and sufficient for C1q expression in purified RGC (Bialas and Stevens, 2013). In vivo, TGF-β receptors (TGFβRRII) are expressed in RGC during development and specific disruption of TGFβRRII in retinal neurons significantly reduces C1q expression, decreases synaptic localization of C1q, and inhibits synaptic pruning in the visual thalamus (Bialas and Stevens, 2013). Other cytokines also play roles in synapse pruning during development. For example, the interleukin-1 family cytokine interleukin-33 (IL-33) orchestrates astrocyte-microglial communication to...
FIGURE 2 | Complement-mediated synapse elimination during development and in neurodegenerative diseases. (A) In the developing brain, astrocytes produce TGF-β that promotes the production of C1q by neurons. Neuron-derived and microglia-derived C1q tags weak synapses activating the classical complement pathway which results in the cleavage of C3 with deposition of C3b at synapses. C3b-tagged synapses are then removed through phagocytosis by microglia expressing the complement receptor CR3. (B) In neurodegenerative diseases, such as Alzheimer’s disease (AD), oAβ promotes the production of C1q by microglia. C1q-tagged synapses are then eliminated by microglia via the classical complement pathway as observed for synapses during development. Also, microglia-derived C1q (together with IL-1α and TNF) induces a subtype of C3+ reactive astrocytes, termed A1 astrocytes, which are neurotoxic. Abbreviations: oAβ, oligomeric amyloid β; TGFβ, transforming growth factor β; IL, interleukin; TNF, tumor necrosis factor.
Pruning of excessive synapses does not only occur during postnatal CNS development but is also involved in the dynamic remodeling of synapses which occurs constantly in mature neurons throughout life as a result of experience and learning (Trachtenberg et al., 2002; Tropea et al., 2010; Fu and Zuo, 2011). A recent study showed that the C1q-dependent classical complement pathway is actively involved in synapse elimination by microglia in the healthy adult hippocampus (Wang et al., 2020). C1q was found to localize to synapses and dendritic spines of engram cells, the neurons responsible for the storage of memory in the hippocampus. The identification of C1q-tagged synaptic components within the lysosomes of microglial cells and the finding that depleting microglia or inhibiting microglia-mediated phagocytosis prevented loss of synapses and memory impairment, indicated that microglia are responsible for the elimination of synapses in the healthy brain and that complement provides the relevant phagocytic signal. Also, specific overexpression of the complement regulator CD55 in engram cells protected from memory loss, further indicating that the elimination of synaptic elements by microglia in the healthy adult hippocampus occurs in a complement-dependent manner. In contrast, inhibiting the activity of engram cells exacerbates memory loss, and this could be blocked by depleting microglia or inhibiting complement pathways in engram cells (Wang et al., 2020). These data indicate that synapse elimination by microglia in the adult brain is also activity-dependent, following similar rules to those in the developing brain (Schafer et al., 2012), thus resulting in the erasure of less-active synapses.

Finally, C1q-dependent reorganization of brain circuitry also occurs during normal aging. C1q levels in the brain dramatically increase during aging (by as much as 300-fold in 24 months old mice compared to early postnatal levels and by 8-fold in hippocampi from 75–77-year-old humans compared to 1–2 months old infants) and C1q can be found close to synapses. Importantly, C1q-deficient mice exhibit enhanced synaptic plasticity and less cognitive and memory decline when aged (Stephan et al., 2013).

**EARLY COMPLEMENT COMPONENTS IN NEURODEGENERATION**

Given that complement plays a key role in developmental synapse elimination, an intriguing hypothesis is that these normal developmental mechanisms may become reactivated during neurodegeneration, driving pathology in settings such as Alzheimer’s disease (AD) and Prion disease. Indeed, in AD and prion disease, neuronal death is preceded by synaptic dysfunction and loss (Schneyer and Hall, 1975; Mallucci, 2009). If synaptic alterations indeed precede and predict neuronal death, then early targeting of the pathways responsible for synaptic injury would be an obvious therapeutic approach to prevent loss of neurons. Since the involvement of key complement factors in neurodegeneration has been previously reviewed (Bonifati and Kishore, 2007; Brennan et al., 2016; Carpanini et al., 2019; Lee et al., 2019) including recently in AD (Tenner, 2020), this section will focus on the emerging evidence that supports a role for complement activation in driving loss of synapses early in the disease.

The initial evidence implicating classical complement pathway components in synaptic loss during neurodegeneration comes from studies in glaucoma, a disease characterized by elevation of intraocular pressure, loss of RGC neurons, and degeneration of the optic nerve, eventually resulting in blindness (Williams et al., 2016). Expression profiling approaches in glaucomatous DBA/2J mice that develop pathology closely resembling the human disease showed that the expression of classical complement components is upregulated in the mouse retina during early glaucoma stages, before detectable signs of neurodegeneration (Steele et al., 2006; Howell G. R. et al., 2011). Furthermore, C1q immunoreactivity was upregulated in the layer of the retina enriched in synapses, specifically post-synaptic connections of RGCs, and increased C1q expression was temporally correlated with a decrease in synaptic density (Stevens et al., 2007). Importantly, the most compelling evidence that complement-mediated elimination of synapses may be an early and injurious event in glaucoma is the demonstration that either deletion of C1q in DBA/2J mice or C1 inhibition in a rat glaucoma model confers neuroprotection in the glaucomatous eye (Howell G. R. et al., 2011; Williams et al., 2016).

As mentioned, the complement system has also been implicated in the pathology of the AD brain where activation of virtually all complement components and activation products have been detected (Veerhuis et al., 2011). In terms of early complement proteins, C1q, C3b, C4b, and properdin have all been localized to key pathological hallmarks of AD, such as amyloid plaques and neurofibrillary tangles (hyperphosphorylated τ) in human AD and animal models, supporting the activation of both classical and alternative pathways in vivo (reviewed in Fonseca et al., 2011; Veerhuis, 2011). In this context, complement activation may be beneficial through the opsonization and clearance of misfolded proteins (Maier et al., 2008; Fu et al., 2012). Also, C1q has been shown to promote the clearance of apoptotic neurons and neuronal blebs in the AD brain (Fraser et al., 2010). Importantly, sites of protein aggregates and dead cells are decorated with membrane-bound and soluble complement regulators, such as CD55, Factor H, and C4 binding protein (C4BP; Strohmeyer et al., 2002; Trouw et al., 2008; Martin and Blom, 2016), demonstrating an orchestrated mechanism of a complement-mediated process comprising activation that is locally controlled to allow clearance of targeted tissue while limiting activation downstream of the C3 and C5 convertases and the associated pro-inflammatory activities.

Studies in mouse models of AD have helped our understanding of the roles and consequences of early complement activation in AD pathology. For example, human amyloid precursor protein (hAPP) transgenic mice deficient in C3 or overexpressing the C5 convertase inhibitor complement receptor 1-related protein y (Crry), showed greater amyloid accumulation and greater cognitive deficits than control mice, suggesting a protective role for C3 activation (Wyss-Coray et al., 2002; Maier et al., 2008). In contrast, C1q deletion in the
Tg2576-transgenic mouse model of AD resulted in diminished plaque burden, a reduced loss of hippocampal synapses, and less cognitive decline relative to C1q sufficient Tg2576 mice, suggesting a detrimental role for C1q in the model (Fonseca et al., 2004). Also, microglia-derived C1q (together with IL-1α and TNF) induced astrocytes to adopt a neurotoxic A1 phenotype (Liddelow et al., 2017). In more recent studies in other AD models, C1q was found to be increased and deposited at synapses before overt plaque deposition, whereas deletion of C1q or C3 or the complement receptor CR3 (also expressed on microglia), reduced the number of phagocytic microglia as well as the extent of early synapse loss, resulting in improved cognitive function (Hong et al., 2016; Figure 2B). Similar evidence of the involvement of early complement components in pathological synapse elimination has been reported in models of frontal temporal dementia (Lui et al., 2016) and West Nile virus infection (Vasek et al., 2016).

Loss of synapses and upregulation of complement components are also major events in other neurodegenerative diseases including Huntington’s disease (Moller, 2010) and Parkinson’s disease (Chao et al., 2014), however, it is unclear whether in these conditions complement plays a crucial role in the elimination of synapses.

A LINK BETWEEN INFLAMMATION AND INJURY IN THE MS-AFFECTED CNS

The past decade has produced a wealth of studies aimed at understanding the link between inflammation and CNS injury in MS, especially in the later disease stages. Most patients present with RRMS, but the disease eventually transitions into a progressive form (secondary progressive multiple sclerosis, SPMS), and a minority of patients develop progressive disease from the onset (primary progressive multiple sclerosis, PPMS; Lublin et al., 2014). While DMT have been successful in controlling the RRMS form of the disease, they, unfortunately, perform poorly in preventing disease progression and accumulation of clinical disability in PPMS and SPMS patients (Macaron and Ontaneda, 2019). If on one hand, these clinical observations have validated a key role of inflammation from the “outside” in the pathogenesis of RRMS, on the other hand, they have raised doubts regarding whether similar mechanisms are at play during the progressive stage of the disease. The reason DMT fail in SPMS and PPMS may be that the inflammatory targets of these DMT are not relevant in progressive forms of MS. Alternatively, inflammation may still be involved during the progressive phase of the disease, but such inflammatory processes become increasingly compartmentalized within the CNS behind a relatively intact blood-brain barrier (Kutzelnigg and Lassmann, 2014). This hypothesis is supported by pathological (Serafini et al., 2004; Lassmann et al., 2007, 2010; Magliozzi et al., 2007, 2010; Howell O. W. et al., 2011; Howell et al., 2015; Lucchinetti et al., 2011; Popescu et al., 2011; Choi et al., 2012; Haider et al., 2016) and imaging studies (Absinta et al., 2015; Zurawski et al., 2020) which—except for some studies (Kooi et al., 2009; Ighani et al., 2020)—have identified aggregates of immune cells in the meninges of MS patients overlaying areas of cortical injury. While these studies implicate inflammatory events within the CNS compartment, this theory still puts the immune system upstream of the disease mechanisms in MS (“outside-in” hypothesis; Kutzelnigg and Lassmann, 2014). Overall, it is now widely accepted that inflammation persists and is linked to tissue injury in both white and gray matter tissue of patients with progressive disease (Magliozzi et al., 2007, 2010; Frischer et al., 2009; Howell O. W. et al., 2011; Machado-Santos et al., 2018); however, the evidence is equally consistent with either the “outside-in” or the “inside-out” paradigm (Stys et al., 2012b). In this section, we present the evidence linking key features of progressive MS white and gray matter pathology with inflammation and specifically complement activation.

MS White Matter

Early pathological studies had already demonstrated that focal demyelinated lesions in the white matter are generally centered on large or medium-sized veins (Rindfleisch, 1863), pointing to a link between events in the periphery and white matter injury. Follow up studies have further highlighted the relationship between inflammation and white matter pathology by showing that lymphocytes and monocytes/macrophages accumulate in the perivascular spaces of medium-sized and small veins within MS plaques. These inflammatory cells can also infiltrate the tissue parenchyma, while local microglial cells become activated (Charcot, 1880). In addition to the lesions, unlesioned areas of the MS-affected CNS also undergo changes that prelude further injury. The so-called “normal-appearing white matter” is characterized by perivascular inflammatory infiltrates, astrocytic gliosis, diffuse axonal injury, and diffuse microglial activation that increases with longer disease duration (Kutzelnigg et al., 2005)—thus, not so normal. Also, within unlesioned tissue, aggregates of HLA+ microglia/macrophages are observed in proximity to microvessels surrounded by lymphocytic infiltrates identifying “(p)reactive lesions” (Figure 3A), so-called since they may or may not represent the earliest stages in the formation of plaques (Barnett and Prineas, 2004; Marik et al., 2007).

Active lesions are highly inflammatory and are found most frequently in RRMS (Figure 3B). They are characterized by loss of myelin, with HLA+ and CD68+ microglia/macrophages infiltrating across the lesion. Foamy microglia/macrophages within an MS lesion indicate ongoing phagocytic activity and myelin proteins are detected within the cytoplasm of these myeloid cells (Luccinetti et al., 2000; Kuhlmann et al., 2017). Histological studies using newly identified markers selectively expressed on microglia, including TIMEM119 which differentiates yolk sac-derived CNS-resident microglia from bone marrow-derived recruited monocytes/macrophages, and the purinergic receptor P2RY12 which identifies a homeostatic microglia phenotype (Butovsky et al., 2014; Masuda et al., 2020), showed that ~45% of macrophage-like cells are derived from the resident microglia pool in active lesions (Zrzavy et al., 2017). In these lesions, microglia show reduced expression of the homeostatic marker P2RY12, which is reacquired in inactive lesions. T cells and CD20+ B cells are also detected within
active lesions (Machado-Santos et al., 2018). While B cells in the lesion are mostly seen in the perivascular space of the central vein, T cells infiltrate the parenchyma in addition to populating the perivascular space. Some CD8+ T cells feature a more tissue-resident memory phenotype (i.e., CD8α/α, CD103+; Machado-Santos et al., 2018). Tissue-resident memory T cells lose expression of surface molecules that are involved in the egress of leukocytes from inflamed tissue (S1P1 or CCR7). These molecular changes have been suggested as a potential mechanism responsible for the compartmentalized inflammatory response in MS lesions (Machado-Santos et al., 2018). In addition to CD8+ T cells, CD4+ T cells are also found in MS lesions and have been shown to produce cytokines such as IL-17 and IL-22 which possibly bind to BBB endothelial cells expressing IL-17 and IL-22 receptors, thereby gaining access to the CNS parenchyma (Kebir et al., 2007). Plasma cells expressing IL-17 and IL-22 receptors, thereby gaining access to the CNS parenchyma (Kebir et al., 2007). Plasma cells are also detected within MS lesions but their phenotype is less well understood (Machado-Santos et al., 2018). Over time, active lesions develop into mixed active/inactive lesions (Figure 3C). Indeed, these types of lesions are most commonly found in patients with advanced (disease duration of more than 10 years) or SPMS disease course. They are characterized by a border of activated HLA+ and CD68+ microglia/macrophages and a hypocellular core. In a subset of these lesions, called slowly expanding or “smoldering”, microglia/macrophages at the rim contain MBP or PLP myelin degradation products in their cytoplasm, indicating either a new wave of inflammation and demyelination, or documenting the last remnant of an earlier demyelinating lesion (Frischer et al., 2015). With time, active and mixed active/inactive lesions transition into inactive lesions (Figure 3D). These are indeed the dominant plaque type in patients with advanced disease (disease duration of more than 15 years) or SPMS without attacks (Frischer et al., 2015). Inactive lesions are demyelinated but hypocellular throughout (Frischer et al., 2015).

Overall the pathology of the white matter shows that inflammation is very much linked to demyelination in the MS brain, but it does not answer whether inflammation is the primary cause of the injury (consistent with the “outside-in” paradigm) or a secondary reaction (consistent with the “inside-out” paradigm).

**MS Gray Matter**

Although gray matter changes in the MS brain were noted early on (Dawson, 1916; Brownell and Hughes, 1962), it was not until the advent of more sensitive imaging and histology techniques that the true extent of gray matter demyelination was appreciated, reaching up to 90% of the cortex in extreme cases (Kidd et al., 1999; Peterson et al., 2001; Bø et al., 2003; Chard and Miller, 2009; Calabrese et al., 2010). Based on the location of the demyelinated area, different types of gray matter lesions have been identified (Bø et al., 2003; Kuhlmann et al., 2017). Subpial lesions, occurring on the surface of the brain and often affecting several adjacent gyri are perhaps the most intriguing since they are unique to MS and not seen in any other neuroinflammatory diseases (Fischer et al., 2013). Therefore, they could hold the key to MS-specific disease mechanisms. Subpial cortical demyelination, although present in earlier stages of MS (Lucchinetti et al., 2011; Popescu et al., 2011), appears to be more dominant in the later progressive stage of the disease (Peterson et al., 2001; Bø et al., 2003; Kutzelnigg et al., 2005). Importantly, subpial changes are not limited to demyelination but also include neuronal (Magliozi et al., 2010), axonal (Magliozi et al., 2007), and synaptic (Wegner et al., 2006; Dutta et al., 2011) injury with the extent of subpial cortical damage now considered to be a major contributor to disease progression in MS including both physical (Harrison et al., 2015) and cognitive (Calabrese et al., 2012) impairments. For example, the hippocampus, which is the portion of the cortex critically important for cognitive functions such as the formation, consolidation, and recollection of memories (Squire et al., 2004), is profoundly affected in MS. Not only is the hippocampus extensively demyelinated (Geurts et al., 2007), but it also shows evidence of neuronal injury (Papadopoulos et al., 2009) and synaptic abnormalities (Dutta et al., 2011). Structural and functional disconnections of the hippocampus from several brain networks have also been revealed by magnetic resonance imaging (MRI) studies (Sicotte et al., 2014).
et al., 2008; Gold et al., 2010, 2014; Longoni et al., 2015). Experimental (Trapp et al., 2007; Werneburg et al., 2020) and post-mortem (Peterson et al., 2001; Werneburg et al., 2020) studies indicate that disconnection of brain networks in MS may be mediated by the loss of synapses via the pruning process, part of which is complement-mediated (see “Evidence Supporting the ‘Inside-Out’ Paradigm” section).

Whether inflammation causes subpial cortical gray matter damage has been debated. When compared with the highly inflammatory features of white matter lesions described above, subpial gray matter lesions are relatively “non-inflammatory” in nature. They lack evidence of major BBB disturbances (van Horssen et al., 2007) and display a paucity of parenchymal immune cell infiltration (Peterson et al., 2001; Bø et al., 2003). Also, current anti-inflammatory treatments that effectively modulate peripheral immunity do not prevent or resolve gray matter damage (Ciotti and Cross, 2018).

One theory supporting a key role of inflammation in subpial cortical pathology, while reconciling pathological and clinical findings of progressive MS, proposes that this injury may be driven by a compartmentalized immune response involving the inflamed leptomeninges within brains that have a relatively intact BBB (Serafini et al., 2004; Lassmann et al., 2007; Magliozzi et al., 2007, 2010; Howell O. W. et al., 2011; Lucchinetti et al., 2011; Popescu et al., 2011; Choi et al., 2012; Absinta et al., 2015; Howell et al., 2015; Haider et al., 2016). Histological examination of autopsy CNS tissue from progressive MS cases have shown evidence of Tertiary Lymphoid Tissues (TLT) in the leptomeninges lining the forebrain (Serafini et al., 2004; Magliozzi et al., 2007), the cerebellum (Howell et al., 2015) and to a lesser extent the spinal cord (Reali et al., 2020). MRI studies have also confirmed the presence of meningeal TLT in the MS brain (Absinta et al., 2015). Importantly, these leptomeningeal TLT are associated with underlying (subpial pattern) demyelination, neuronal loss, and a gradient of microglial activation from the subpial area moving inward into the tissue (Magliozzi et al., 2010; Howell O. W. et al., 2011). The meningeal TLTs harbor B cells, T cells, dendritic cells, macrophages, monocytes, plasma cells, and stromal cells that resemble Follicular Dendritic Cells (FDC) normally found in germinal centers (Serafini et al., 2004; Magliozzi et al., 2007; Howell O. W. et al., 2011; Lucchinetti et al., 2011; Lagumersindez-Denis et al., 2017; Reali et al., 2020).

While germinal center environments can support the secondary diversification of B cell receptors (affinity maturation and class switch) in the context of some animal models of MS (Galicia et al., 2013), a study using post-mortem samples suggested that the majority of these secondary diversification events are occurring within the draining cervical lymph node rather than in the CNS itself (Stern et al., 2014). Nonetheless, it has been shown that within TLT, B cells proliferate and CD21+ CD35+ FDC-like stromal cells produce the chemokine CXCL13, suggestive of an immunocompetent stromal cell niche that serves to attract and retain leukocytes, supporting their survival and proliferation (Serafini et al., 2004).

An important function of cells that reside within the meninges is the ability to secrete by-products which are released into the CSF and may diffuse freely throughout the subarachnoid space. If one considers that there are regions of reduced CSF flow, particularly within brain sulci, such by-products may become concentrated in “hot spots,” resulting in the trapping of immune cells (Howell O. W. et al., 2011). These soluble molecules are potentially inflammatory, cytotoxic, myelinotoxic but also potentially anti-inflammatory and neuroprotective. Indeed, recent studies analyzing the content of CSF in MS patients have shown that high cortical lesion load correlates with proinflammatory cytokines (IFNγ, TNF, IL2, and IL22; Gardner et al., 2013; Magliozzi et al., 2018), molecules related to sustained B-cell activity and lymphoid-neogenesis (CXCL13, CXCL10, LTA, IL6; Magliozzi et al., 2018), B-cell survival factors (BAFF; Magliozzi et al., 2019), factors indicative of BBB leakage (fibrin, complement and coagulation factors; Magliozzi et al., 2019) and iron-related proteins (free-hemoglobin and haptoglobin; Magliozzi et al., 2019), but also anti-inflammatory mediators such as IL10 (Magliozzi et al., 2019). In line with the latter, regulatory T (Treg) cells producing IL-10 have been detected in the MS CSF (Feger et al., 2007) although deficits of their regulatory functions and migratory properties have also been reported in MS (Viglietta et al., 2004; Astier et al., 2006; Martinez-Forero et al., 2008; Venken et al., 2008; Schneider-Hohendorf et al., 2010).

In summary, while the spatial association between TLT and subpial injury has suggested a potential role in initiating and/or modulating demyelinating pathology in the gray matter, these same pathological features are equally consistent with a potential reaction of the immune system in the meningeal compartment to areas of pre-existing injury in the underlying cortex. Without longitudinal studies, it is impossible to conclude whether these TLT sites preceed the formation of subpial lesions, or whether they represent an attempt of the immune system to repair an existing injury. If the latter scenario is true, then the presence of meningeal TLT reacting to a site of primary injury would be consistent with the “inside-out” paradigm. Studies in animal models that replicate meningeal TLTs and subpial pathology (Pikor et al., 2015; Ward et al., 2020), emerging MRI approaches to identify and perhaps monitor the formation of TLT in patients (Absinta et al., 2015), and multi-dimensional technologies to phenotype cells in situ (Ramaglia et al., 2019) will be important to unravel the nature of the relationship between TLTs and subpial injury in MS.

COMPLEMENT IN MS

A contribution of the complement system to the pathology of MS has long been suspected based on pathological and serological studies in MS as well as functional studies in EAE. However, the extent and trigger(s) of complement activation and the pathways involved in specific disease processes remain unclear. In particular, the relative contribution of serum-derived complement vs. CNS-derived complement in initiating as well as propagating MS disease processes remains to be determined. In this section, the evidence is reviewed that supports a role for complement in both “outside-in” and “inside-out” pathological mechanisms of the MS-affected CNS.
Evidence Supporting the “Outside-In” Paradigm

While the specific antigens responsible for initiating the immune response in MS remain unidentified, MS patients commonly have oligoclonal immunoglobulin G in the CSF (Joseph et al., 2009) and several studies have demonstrated antibodies to myelin and other CNS autoantigens in patients (reviewed in Berger and Reindl, 2007). Moreover, T cells specific for myelin antigens have been detected in the blood of MS patients (reviewed in Kaskow and Baecher-Allan, 2018) and found to produce inflammatory mediators such as granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF), interferon-gamma (IFN-γ), interleukin-2 (IL-2) and C-X-C chemokine receptor type 4 (CXCR4; Galli et al., 2019). Importantly, transient gadolinium-enhancing lesions on magnetic resonance scans have indicated BBB breakdown, especially in RRMS patients (Stone et al., 1995). In line with this observation, immunoglobulins and complement deposits have been described in MS lesions (Compston et al., 1989; Storch et al., 1998; Lucchinetti et al., 2000; Prineas et al., 2001; Ingram et al., 2014; Michailidou et al., 2015, 2017; Watkins et al., 2016; Loveless et al., 2018). Also, plasma proteins including Factor XIIa, plasmin, and thrombin, which are part of the coagulation pathway, could leak from the circulation into the brain parenchyma through a compromised BBB, particularly in RRMS patients, triggering direct activation of C3 (Markiewski et al., 2007; Amara et al., 2010) and C5 (Huber-Lang et al., 2006). Notably, in situ evidence of antibody and complement deposits within MS plaques in close association with capillary endothelial cells (Compston et al., 1989; Storch et al., 1998),

![FIGURE 4](https://www.frontiersin.org/article/10.3389/fncel.2020.574765)
have suggested a role for an “outside-in” complement/antibody-mediated injury in lesions (Figure 4). Moreover, complement components and regulators are elevated systemically and in the CSF of MS patients (Ingram et al., 2009, 2010a,b; Zelek et al., 2019) and early complement pathway gene variants (C3, C1QA, and CR1) have recently been associated with structural and functional measures of MS severity (Fitzgerald et al., 2019), indicating an inherent susceptibility to complement-mediated injury in some patients.

A detailed pathological analysis performed by Lucchinetti et al. (2000) on active and early demyelinating MS white matter lesions from a cohort of patients with relatively short disease duration (the mean disease duration before autopsy or biopsy was 39 and 9 months, respectively), identified a histological pattern (pattern II) of lesions with prominent complement activation in a distinct but large subgroup (pattern I: 4%, pattern II: 59%, pattern III: 26%, pattern IV: 11% of total autopsy cases analyzed) of MS patients. In these lesions, the terminal complement TCC/MAC was associated with phagocytic macrophages. These findings suggested that complement activation may be one of at least four possible mechanisms of tissue injury leading to demyelination. Other patterns involve activated macrophages/microglia (but not complement activation; pattern I), apoptotic (pattern III), or non-apoptotic (pattern IV) oligodendrocyte degeneration (Lucchinetti et al., 2000). While this study highlighted the heterogeneity of early MS lesions, a subsequent report by Breij et al. (2008) based on the analysis of white matter lesions in autopsy tissue from MS patients with long disease duration (mean disease duration was 22 years), showed that complement deposits can be found consistently in areas of demyelination across all patients with established MS lesions. The authors suggested that the previously reported heterogeneity of white matter lesions (Lucchinetti et al., 2000) may have been specific to early disease and was therefore not seen in their autopsy samples. Subsequent immunohistochemical studies analyzing the presence and localization of key complement components (C3, factor B, C1q), activation products (C3b, iC3b, C4d, TCC/MAC), regulators (factor H, C1-inhibitor, clusterin) and receptors (C3aR, C5aR1) in established MS lesions found that, although variable between individuals, the presence of complement proteins and activation products in and around white matter lesions is a consistent feature of progressive MS (Ingram et al., 2014; Loveless et al., 2018), echoing the conclusions from Breij et al. (2008).

Evidence for complement activation in MS gray matter has also been mixed. Initial histological studies reported evidence of activated complement (C4d) on oligodendrocytes at the edge of small cortical plaques (Schwab and McGeer, 2002). Subsequent studies in autopsy tissue from MS patients with the long-standing disease showed little evidence for complement activation products in purely cortical lesions (Brink et al., 2005). More recent studies in lesions from progressive MS patients showed evidence of C1q deposition on neurons, as well as complement activation fragments (Bb, C3b) on neurons and glia, and TCC/MAC on neurons across cases analyzed (Watkins et al., 2016).

Intriguingly, complement may also play a role in the context of compartmentalized inflammation within meningeal TLTs (see “MS Gray Matter” section; Ramaglia et al., in press a). Using the Th17 cell A/T model to induce EAE in SJL/J mice, Pikor et al. (2015) demonstrated that at the earliest stages of CNS autoimmunity, meningeal TLTs contain cells that are positive for the complement component C3. Although the nature of the C3+ cells within TLTs was not explored, deposited C3 could modulate adaptive immune cell responses. For example, activated C3 (C3d) bound to antigens has been shown to regulate B cell function by lowering the threshold for B cells activation through its interaction with the CR2 co-receptor on B cells (Dempsey et al., 1996). In terms of T cells, intracellular expression and activation of C3 have been implicated in the control of human adaptive T cell responses (Liszewski et al., 2013). One hypothesis is that C3a-like and C3b-like products are continuously generated intracellularly within endosomal/lysosomal compartments at low levels in resting T cells via cathepsin-L (CTSL)-mediated cleavage of C3; the C3a-like product engages the lysosomal-expressed G-protein-coupled C3a receptor (C3aR) to sustain the tonic activity of mammalian target of rapamycin complex 1 (mTORC1) and survival of circulating T cells at steady-state (Liszewski et al., 2013). The CTSL-mediated activation of C3 is increased by T cell receptor (TCR) activation and CD28 co-stimulation. C3 activation fragments then shuttle to the cell surface where they engage their respective receptors, C3aR (which binds C3a) and CD46 (which binds C3b), to induce IFN-γ production and T helper type 1 (Th1) differentiation (Liszewski et al., 2013). The same pathway could function in human CD8+ T lymphocytes. According to this hypothesis, C3 protein is processed intracellularly into activation fragments that engage the same receptors in an autocrine/paracrine manner and drives IFN-γ production and cytolytic activity (Arbore et al., 2018).

In line with the potential production and secretion of complement proteins by immune cells residing in meningeal TLTs, a recent proteomic CSF profiling in early MS patients showed that among 227 proteins differentially expressed between the patients with high vs. low cortical lesion load, 30% were related to the complement cascade, suggesting that in addition to other soluble mediators, complement positively correlates with cortical damage at early disease stages (Magliozzi et al., 2019), possibly by diffusing through a disrupted glial limits into the subpial cortex causing injury. Other proteins identified in the CSF of MS patients included the blood coagulation factor fibrinogen (Magliozzi et al., 2019), suggesting that the extrinsic pathway of the coagulation system may also be involved in pathological processes occurring in the MS brain. From the earliest studies using experimental animal models of demyelination, particularly EAE, it was already noted that perivascular deposition of insoluble fibrin [produced from fibrinogen by perivascular tissue factor and procoagulant proteins (Thomas et al., 1993; Akassoglou and Strickland, 2002)], occurred in conjunction with paralytic episodes (Paterson, 1976). Further studies causing abnormal cleavage and degradation of fibrinogen (Adams et al., 2004) or blocking the conversion of fibrinogen into insoluble fibrin (Akassoglou et al., 2004; Yang et al., 2011), reduced EAE severity.
Experimental studies into the mechanisms of fibrin-induced injury performed by genetically blocking the ability of fibrin to bind to the CD11b/CD18 integrin receptor on microglia and macrophages (without affecting the binding of other ligands to CD11b/CD18), resulted in reduced microglial activation, decreased axonal damage, less demyelination, and reduced paralysis, demonstrating that fibrinogen entry into the CNS and subsequent CD11b-mediated microglial activation may be key upstream molecular events that drive inflammatory demyelination (Adams et al., 2007; Davalos et al., 2012). More recently, it was shown that fibrinogen stored in extracellular vesicles from blood plasma induces encephalitogenic CD8⁺ T cells, contributing to the perpetuation of neuroinflammation and relapses in response to immunization with a myelin antigen (MOG35–55; Willis et al., 2019).

Indications that complement plays a role in the pathology of MS comes from experimental studies in animal models of demyelination, particularly EAE. From initial studies that have used cobra venom factor as a tool to consume complement, to subsequent studies that have used either untargeted or targeted pharmacological inhibition of complement activation or that have used genetic deletion of complement components and regulators, it has become apparent that reducing complement activation in EAE is protective (reviewed in Ingram et al., 2009). In particular, the “outside-in” role for systemically-derived complement in models of demyelination comes from recent evidence in the chronic relapsing EAE (crEAE) model of demyelination in Biozzi AB/H mice (Michailidou et al., 2018). In these mice, immunization with homogenates of the syngeneic spinal cord (SCH) in complete Freund’s adjuvant induces a chronic relapsing form of EAE (Baker et al., 1990), which pathologically is characterized by inflammatory demyelinating lesions in the spinal cord and substantial axonal injury (Jackson et al., 2009). In terms of inflammation, these spinal cord lesions are populated by macrophages, CD4⁺ T lymphocytes (Butter et al., 1991), and deposits of TCC/MAC (Ramaglia et al., 2015). Notably, post-symptomatic treatment of crEAE with an antisense oligonucleotide that specifically targets CNS-extrinsic production of murine C6 mRNA (a component necessary for the formation of the TCC/MAC complex), inhibited TCC/MAC deposition inside the CNS, prevented relapses and protected from relapse-induced axonal and synaptic damage (Michailidou et al., 2018). Further analysis showed that this protection was achieved by impeding the activation of parenchymal neuroinflammatory responses, including the Nod-like receptor protein 3 (NLRP3) inflammasome (Michailidou et al., 2018). Therefore antisense-mediated knockdown of C6 expression outside the CNS is sufficient to impede neuroinflammation in the crEAE model of MS, pointing to a pathogenic role of the serum-derived terminal complement components in this model of demyelination.

**Evidence Supporting the “Inside-Out” Paradigm**

Evidence that complement may be triggered as a reaction to primary damage within the CNS derives from studies in models of traumatic nerve or CNS injury. In these models, the primary injury is a mechanical insult either delivered by a compression of the sciatic nerve, inducing Wallerian degeneration (Ramaglia et al., 2007) or by a weight drop on a closed skull in the case of a traumatic brain injury (TBI; Fluiter et al., 2014) or on the spinal cord in the case of a spinal cord injury (SCI; Qiao et al., 2010). In each instance, the mechanical injury results in the activation of the complement system to completion including the formation of TCC/MAC (Anderson et al., 2004; Ramaglia et al., 2007; Nguyen et al., 2008; Fluiter et al., 2014). Importantly, inhibition of the complement system at various levels of the cascade results in reduced pathology and ameliorated clinical outcome in rodent models of nerve/CNS injury. For example, broad inhibition of the complement system by targeting the C3 convertase reduces neutrophil accumulation (Kaczorowski et al., 1995), promotes neuronal survival, induces neuroprotective intracerebral gene expression, and ameliorates neurological outcome after TBI (Leinhase et al., 2006). More specific inhibition of the complement cascade targeting only the alternative pathway of complement also led to substantial attenuation of cerebral tissue damage and neuronal cell death, inducing a neuroprotective pattern of intracerebral gene expression following TBI (Leinhase et al., 2007). Alternative strategies that have targeted specific pro-inflammatory arms of the complement system, such as inhibiting the anaphylatoxin C5a, have also shown protective effects by reducing neutrophil extravasation into the brain parenchyma after TBI (Selwood et al., 2004). Inhibition of the most downstream component of the terminal complement activation pathway, the formation of the membrane attack complex (TCC/MAC), is also sufficient to prevent secondary neurologic damage and neurologic deficit after TBI (Fluiter et al., 2014; Ruseva et al., 2015). In the case of SCI, deletion of C1q resulted in greater locomotor recovery and better histological outcome compared to wild-type mice after a contusion injury of the spinal cord (Galvan et al., 2008), suggesting that initiation of the classical complement pathway via C1q is detrimental to recovery after SCI. Involvement of the classical pathway of complement in determining pathology after SCI was also confirmed by the protective effects of C1 esterase inhibitor (C1-INH) on pathology and function after traumatic SCI in the rat (Tei et al., 2008). Blocking activation of the complement system at its core by deleting C3 or via targeted inhibition of C3 activation to sites of C3 deposition (with CR2-Crry) significantly reduced necrosis, demyelination, and neutrophil infiltration, improving functional outcome after SCI in mice (Qiao et al., 2006). Also, deletion of the alternative pathway component Factor B or pharmacological inhibition of the alternative pathway with a monoclonal antibody against Factor B reduced tissue damage and demyelination, reduced inflammatory cell infiltrate, and improved functional recovery after SCI in mice (Qiao et al., 2010). On the contrary, deletion of the TCC/MAC complement regulator CD59a resulted in significantly increased tissue injury and impaired functional recovery compared to wild-type mice (Qiao et al., 2010), also implicating the terminal complement pathway in the nerve injury caused by spinal cord trauma. Likewise in the peripheral nerve, blocking the C3 convertase (Ramaglia et al., 2008) or the TCC/MAC (Ramaglia et al., 2007) reduces pathology and...
neurological symptoms after trauma, whereas deletion of CD59a exacerbates Wallerian degeneration (Ramaglia et al., 2009a). Interestingly in the peripheral nerve, inhibition of TCC/MAC also accelerates the regeneration of the nerve (Ramaglia et al., 2009b), further proving a detrimental role of complement activation during nerve damage. Therefore, complement can be activated by degenerating axons in the absence of antibodies, demonstrating a reaction to altered-self epitopes. In the context of MS, a primary injury to myelinated axons or axons undergoing Wallerian degeneration could trigger secondary complement activation (Figure 5A).

Additional evidence that CNS-intrinsic complement activation may occur independently of immune cell-mediated demyelination comes from observations in the normal-appearing white matter or periplaque of MS brains. These regions are often reported to contain clusters of microglia (also called microglial nodules) around damaged axons coated with complement deposits (C3d; Prineas et al., 2001; Barnett et al., 2009; Ramaglia et al., 2012). While these C3d-associated microglial nodules have been proposed to play a role at the earliest stage of lesion formation (Marik et al., 2007; Barnett et al., 2009), a more in-depth analysis showed that, although nodules localize on axons with impaired transport, they likely do not reflect an acute attack against myelinated axons because they occur in chronic but not an acute disease and because they can also be detected in the brains of patients with non-demyelinating diseases such as ischemic stroke (Michailidou et al., 2017). Therefore, it was concluded that it is unlikely that microglial nodules around C3d-coated axons drive the formation of new lesions but could represent a physiological mechanism to remove irreversibly damaged axons in chronic disease (Michailidou et al., 2017; Figure 5B).

In the gray matter, neurons and synapses could be potential hotspots of complement-mediated primary cytodegeneration (Figure 5C). Spurred by evidence implicating early complement components in the pruning of synapses during development (Stevens et al., 2007; Schafer et al., 2012), adulthood (Wang et al., 2020), normal aging (Stephan et al., 2013; see “Early Complement

![Figure 5](https://example.com/fig5.png)

**Figure 5** | A role for complement in the “inside-out” paradigm of demyelination and synapse loss in MS. (A) The “inside-out” model argues that a so far unknown primary cytodegenerative event leads to myelin changes or Wallerian degeneration or retrograde degeneration which exposes altered highly antigenic myelin epitopes. In this scenario, the complement system would participate in the secondary autoimmune and inflammatory response by tagging myelin and promoting its clearance by phagocytes. (B) In the normal-appearing white matter, complement (particularly activated C3) tags axons that may be damaged as a result of Wallerian degeneration or retrograde degeneration. C3-tagged altered myelin is then removed by clusters of microglia (also called microglial nodules). (C) In the gray matter, neurons and synapses could be potential hotspots of complement-mediated primary cytodegeneration. (C’) Synapses (of the visual thalamus) are tagged by C3b and engulfed by microglia. Tagging of synapses by C1q has also been reported in the MS hippocampus but its role in the early engulfment of synapses has not yet been investigated. Also, microglia-derived C1q (together with IL-1α and TNF) induces a subtype of C3+ reactive astrocytes, termed A1 astrocytes, which are neurotoxic. (C”) Neurons upregulate C1q by an unknown trigger. C1q can then potentially bind to its receptor (gC1qR) on the surface of mitochondria triggering the production of ROS which in turn can induce myelin and neuronal damage. Abbreviations: ROS, reactive oxygen species.
Components in the Developing, Adult, and Normal Aging CNS” section) and neurodegeneration (Hong et al., 2016; see also “Early Complement Components in Neurodegeneration” section), studies of early complement components in the myelinated and demyelinated MS hippocampus were performed; these showed that C1q and C3d are deposited at synapses that localize within microglial processes and lysosomes particularly in the CA2/CA3 hippocampal subfield, supporting a role for complement-mediated elimination and degradation of synapses by microglia (Michaillidou et al., 2015). A more recent study showed that in the MOG35–55 EAE mouse model of demyelination synapses are reduced while C1q and C3 are both upregulated in the CA1 hippocampal subfield at 28–30 days post-immunization. Notably, C3 deletion rescued synapse loss and improved clinical outcomes (Hammond et al., 2020). However, since complement C3 plays a broader role in the dynamics of EAE, it is difficult to ascribe the protective effects of C3 deletion to a local role of C3 within the hippocampus. Studies at early (pre-onset) stages of EAE or in non-immune mediated models of hippocampal demyelination (such as the cuprizone model) may be more informative at pinpointing the kinetics of complement-dependent pruning of synapses in MS. Indeed, a recent study analyzing brain tissue at the onset of moderate clinical symptoms of models of demyelination showed that synaptic material is tagged by C3 (but not by C1q) and is engulfed by microglia in the retinogeniculate system of models of demyelination (Werneburg et al., 2020), dissociating complement activation at synapses from immune-mediated demyelination in this model (Figure 5C).

What initiates complement activation in the MS hippocampus and visual thalamus is unknown but is an important question. The observations that neuronal production of C1q has been observed in the MS hippocampus (Michaillidou et al., 2015) and in the retinogeniculate system (Bialas and Stevens, 2013) would suggest that the signal to eliminate synapses originates from the target neuron. The mechanisms responsible for the recruitment of C1q to synapses also remains unknown. Antibodies are the obvious candidate, but deposits of immunoglobulins were not detected in the MS hippocampus. An alternative target of C1q is an apoptotic signal on the surface of dead or dying cells, such as the previously identified ceramide transporter protein (Bode et al., 2012a; You et al., 2012), and in addition to neurons, copper ions are known to desensitize NMDA receptors (Stys et al., 2005; Micu et al., 2006), it was suggested that dysregulation of copper homeostasis may result in chronic stress (Mahad et al., 2009; Witte et al., 2009; Fischer et al., 2012) and changes in the glutamate neurotransmitter system (Dutta et al., 2011) have been reported in MS. Based on these findings it is tempting to speculate that similar pathways may regulate synaptic pruning in the MS hippocampus. Also, poor tissue oxygenation (hypoxia) and “virtual hypoxia” could cause axonal changes that could potentially be targeted by the complement system. Hypoxia could arise partly from narrow-end arteries and arterioles that are vulnerable to oxygen desaturation or from veins that can deplete oxygen from the surrounding tissue (Martínez Sosa and Smith, 2017). “Virtual hypoxia” could arise from increased energy demand of demyelinated axons to generate action potentials and reduced axonal ATP production (Trapp and Stys, 2009).

In the context of the “inside-out” paradigm, a potential mechanism that has been suggested as a trigger of cytodegeneration is a putative deficiency of copper ions in the MS-affected CNS, with copper deficiency promoting demyelination and loss of myelinating oligodendroglia. This hypothesis originates from observations in the cuprizone model of demyelination, where the copper chelator cuprizone, results in varying degrees of oligodendroglial damage and demyelination in the CNS, with limited inflammation (Kipp et al., 2009). Since copper ions are known to desensitize NMDA receptors (Stys et al., 2012a; You et al., 2012), and in addition to neurons, oligodendrocytes and the myelin sheath also express NMDARs (Kardottir et al., 2005; Micu et al., 2006), it was suggested that dysregulation of copper homeostasis may result in chronic overactivation of these receptors, leading to excitotoxicity (Stys et al., 2012b). In this setting, it is tempting to speculate that the elimination of synapses by complement may be initially a protective mechanism that lowers excessive excitatory activity since such excitatory activity can eventually lead to pathological synaptic alterations. This hypothesis, however, remains to be tested.

**INTRACELLULAR C1q IN THE CNS—“INSIDE THE INSIDE”**

As mentioned, C1q is at least partially produced by cortical neurons in MS (Michaillidou et al., 2015; Watkins et al., 2016) and neuronal production of C1q has also been observed in the retinogeniculate system (Bialas and Stevens, 2013). Intracellular C1q is emerging as an important modulator of cell metabolism particularly by acting on mitochondrial activity. For example, intracellular C1q can be recognized by the mitochondrially
is involved in MS, either as part of a primary autoimmune
Regardless of the modality in which the complement system
IN MS
TARGETING THE COMPLEMENT SYSTEM
APPROACHES TO THERAPIES
observed in the MS-affected CNS remains to be investigated
intracellular C1q plays a role in the ROS-mediated damage
apoptosis (Lucchinetti et al., 2000) occur in MS, whether
pathway (Hou et al., 2014). Importantly, CTRP3 knockdown
from ischemia-induced apoptosis (Feng et al., 2016), and it protects mesenchymal stem cells
mitochondria in smooth muscle adipocytes (Nishimoto et al., 2017), it has also been shown
also induce mitochondrial injury by disrupting mitochondrial enzymes, by modifying mitochondrial proteins and accelerating their degradation. Free radicals can also interfere with de novo synthesis of respiratory chain components and can directly induce mitochondrial DNA damage (Bolaños et al., 1997; Smith et al., 1999). Therefore, the role of intracellular C1q in driving the production of ROS is consistent with the evidence of ROS and ROS-mediated injury in MS tissue.

In addition to C1q, C1q-TNF family proteins [also known as C1q-TNF-related protein (CTRP) family] play many roles in both immunity and metabolism. These molecules are structurally related to both C1q and TNF and form hybrid proteins (recently reviewed in Schaffler and Buechler, 2012). The C1q-TNF-CTRP family member, CTRP3, negatively regulates lipid metabolism by downregulating PPAR-γ and C/EBPα in adipocytes (Nishimoto et al., 2017), it has also been shown to mediate mitochondrial ROS production in smooth muscle cells (Feng et al., 2016), and it protects mesenchymal stem cells from ischemia-induced apoptosis via activation of the PI3K/Akt pathway (Hou et al., 2014). Importantly, CTRP3 knockdown by siRNA in bone marrow-derived mesenchymal stem cells proved that intracellular and/or autocrine C1q synthesis rather than systemic production was important for its function (Hou et al., 2014). While altered lipid metabolism (Kooij et al., 2019), mitochondrial ROS production (see above), and apoptosis (Lucchini et al., 2000) occur in MS, whether intracellular C1q plays a role in the ROS-mediated damage observed in the MS-affected CNS remains to be investigated (Figure 5C”).

**APPROACHES TO THERAPIES**
**TARGETING THE COMPLEMENT SYSTEM IN MS**

Regardless of the modality in which the complement system is involved in MS, either as part of a primary autoimmune attack to the CNS (outside-in) or as part of a secondary event triggered by primary changes in the CNS (inside-out), uncontrolled activation can ultimately exacerbate an injury. Thus inhibition of complement may be protective. Identification of MS patients that may benefit from complement therapy, or pin-pointing a time-frame when complement therapy may be appropriate, would be invaluable in guiding clinicians to decide whether and when an anti-complement drug might be effective in a given patient. Measuring complement may also aid diagnosis, assessment of prognosis, and help in the monitoring of treatment response in this complex and heterogeneous disorder. Besides, although not reviewed here in detail, complement can also exert protective functions in the brain (reviewed in Ingram et al., 2009). Therefore, targeting complement-mediated injurious signals while maintaining potential protective roles, would have to be taken into account when designing an appropriate complement therapy.

Various complement proteins have also been considered as biomarkers of disease activity. One challenge in the identification of complement as a serological or CSF biomarker is the fact that complement components are acute-phase proteins whose synthesis and consumption are both increased in response to inflammation. As a consequence, the serum and CSF levels of a given complement component will be influenced by bouts of active inflammation, including infection. Nevertheless, while earlier studies showed inconsistent results (Jans et al., 1984; Jongen et al., 2000), more recent analysis on well-powered cohorts stratified based on clinical course and compared to age-matched controls have shown more consistent outcome for levels of complement components, activation products and regulators in serum and CSF (Ingram et al., 2010a,b, 2012). Systemic complement profiling has shown increased plasma levels of C3, C4, C4a, C1 inhibitor, and factor H, while levels of the terminal component C9 were reduced in MS patients compared with controls. Importantly, combined profiling of these analytes produced a statistical model with a predictive value of 97% for MS and 73% for clinical relapse when combined with selected demographic data (Ingram et al., 2012). Interestingly, plasma C4a levels were found to be raised only in acute relapse, decreasing over 2 months (Ingram et al., 2010b) and serum factor H levels were capable of distinguishing secondary progressive from relapsing-remitting disease (excluding patients in clinical relapse) with a sensitivity of 89.41%, a specificity of 69.47% and a positive predictive value of 72.38% (Ingram et al., 2010a). Therefore, specific complement components may be an effective indicator of progression or relapse and accessible biomarker to stratify patients, providing objective evidence to help guide therapeutic decisions.

While there is a growing complement therapeutics industry with many new emerging drugs (Carpanini et al., 2019), to date CNS targets have been largely ignored. Drug delivery across the BBB is a major challenge that needs to be considered when designing CNS-directed therapeutics. Perhaps therapies should target areas of pathology, as described for the fusion proteins linking CR2 (localizes to C3 activation products in tissues) with a complement regulator (see Werneburg et al., 2020), or they should target complexes, for example, TCC/MAC, which
CONCLUSIONS AND FUTURE DIRECTIONS

In conclusion, while it is clear that the complement system is involved in the pathology of the MS-affected CNS, the pathways that the complement system engages to aid in the clearance of myelin or to shape synaptic circuits in various regions of the MS brain can differ substantially. Increasing awareness of the distinct roles of complement components in normal brain development and in neurodegenerative disorders may guide our understanding of similar pathological processes in MS. Understanding the relative contribution of serum-derived complement proteins vs. those produced locally by brain resident cells across MS disease stages and how to complement gene expression is regulated in the brain will be important questions for future research. For example, conditional knock out mice in which a particular complement gene can be inactivated in specific cell types of the brain could help tease apart the contributions of complement derived from brain-resident cells vs. that derived from the periphery. Also, viral vector approaches that enable the expression of complement regulators at targeted surfaces within the brain could help test the effect of local complement activation while maintaining intact peripheral complement functions. As a complementary approach, bone marrow chimeras or targeted inhibition of hepatic source of complement could help modulate peripheral complement while maintaining intact complement produced by cells within the brain. The added knowledge may help answer the question of whether MS is initiated by “outside-in” or “inside out” disease mechanisms. The current knowledge is equally consistent with either paradigm, and it is likely that both mechanisms jointly contribute to the variable course of MS.

AUTHOR CONTRIBUTIONS

VR, JLG and BPM wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

VR’s and JLG’s research is currently supported by the Global Multiple Sclerosis Innovation (GMSI) award and the Multiple Sclerosis Society of Canada Research Foundation (MSSRF). VR’s research is also supported by the National Multiple Sclerosis Society (RG-1602-07777 in collaboration with Prof. Maarten Kole at the Netherlands Institute of Neuroscience in Amsterdam, The Netherlands). BPM is supported by the UK Dementia Research Institute.
Bolaños, J. P., Almeida, A., Stewart, V., Peuchen, S., Land, J. M., Clark, J. B., et al. (1997). Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J. Neurochem. 68, 2227–2240. doi: 10.1046/j.1471-4159.1997.68062222.x

Bonfati, D. M., and Kishore, U. (2007). Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 44, 999–1010. doi: 10.1016/j.molimm.2006.03.007

Breij, E. C., Brink, B. P., Veehuis, R., van den Berg, C., Vloet, R., Yan, R., et al. (2008). Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 63, 16–25. doi: 10.1002/ana.21311

Brennan, F. H., Lee, J. D., Ruitenberg, M. J., and Woodruff, T. M. (2016). Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin. Immunol. 28, 292–308. doi: 10.1016/j.smim.2016.03.015

Brink, B. P., Veehuis, R., Breij, E. C., van der Valk, P., Dijkstra, C. D., and Bo, L. (2005). The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol. 64, 147–155. doi: 10.1093/jn/64.2.147

Brownell, B., and Hughes, J. T. (1962). The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 25, 315–320. doi: 10.1136/jnnp.25.4.315

Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., et al. (2014). Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131–143. doi: 10.1038/nn.3599

Butter, C., Baker, D., O’Neill, J. K., and Turk, J. L. (1991). Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J. Neurosci. 10, 94–112. doi: 10.1016/0022-5191(91)90209-p

Calabrese, M., Filippi, M., and Gallo, P. (2010). Cortical lesions in multiple sclerosis. Nat. Rev. Neurol. 6, 438–444. doi: 10.1038/nrneurol.2010.93

Calabrese, M., Poretto, V., Favaretto, A., Alessio, S., Bernardi, V., Romualdi, C., et al. (2012). Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135, 2952–2961. doi: 10.1093/brain/aws246

Carpanini, S. M., Torvell, M., and Morgan, B. P. (2019). Therapeutic inhibition of the complement system in diseases of the central nervous system. Front. Immunol. 10:362. doi: 10.3389/fimmu.2019.00362

Chao, Y., Wong, S. C., and Tan, E. K. (2014). Evidence of inflammatory system involvement in Parkinson’s disease. Biomed. Res. Int. 2014:308654. doi: 10.1155/2014/308654

Charcot, J. M. (1880). Leçons sur les Maladies du Systeme Nerveux Faites a la Salpêtrière. 4th Edn. Paris: Adrien Delahaye et E. Lecrosnier.

Chard, D., and Miller, D. (2009). Grey matter pathology in clinically early multiple sclerosis. Ann. Neurol. 66, 445–454. doi: 10.1002/ana.22337

Dawson, J. D. (1916). The histology of disseminated sclerosis. Brain 39, 271–296. doi: 10.1093/brain/awt110

Engelhardt, B., Bara, R. O., Bechtman, L., Fligel, A., Laman, J. D., and Weller, R. O. (2016). Vascular, glial and lymphatic immune gateways of the central nervous system. Acta Neuropathol. 132, 317–338. doi: 10.1007/s00401-016-1606-5

Engelhardt, B., and Coine, C. (2011). Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS fluids. Cerebrospinal Fluids Barriers CNS 8:4. doi: 10.1186/2045-8118-8-4

Ertürk, A., Wang, Y., and Sheng, M. (2014). Local pruning of dendrites and spines by caspase-3-dependent and proteasome-limited mechanisms. J. Neurosci. 34, 1672–1688. doi: 10.1523/JNEUROSCI.3121-13.2014

Fenger, U., Luther, C., Poeschel, S., Melms, A., Tolosa, E., and Wiendl, H. (2007). Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin. Exp. Immunol. 147, 412–418. doi: 10.1111/j.1365-2299.2006.03271.x

Feng, H., Wang, J.-Y., Zheng, M., Zhang, C.-L., An, Y.-M., Li, L., et al. (2016). CTRP3 promotes energy production by inducing mitochondrial ROS and up-expression of PGC-1α in vascular smooth muscle cells. Exp. Cell Res. 341, 177–186. doi: 10.1016/j.yexcr.2016.02.001

Filippello, F., Morini, R., Corradini, I., Zerbi, V., Canzi, A., Michalski, B., et al. (2018). The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. Immunity 48, 979.e8–991.e8. doi: 10.1016/j.immuni.2018.04.016

Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drekhage, J., et al. (2012). NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135, 886–899. doi: 10.1093/brain/awt012

Fischer, M. T., Wimmer, I., Hofberger, R., Gerlach, S., Haider, L., Zrzavy, T., et al. (2013). Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 136, 1799–1815. doi: 10.1093/brain/awt110

Fitzgerald, K. C., Kim, K., Smith, M. D., Aston, S. A., Fioravante, N., Rothman, A. M., et al. (2019). Early complement genes are associated with visual system degeneration in multiple sclerosis. Brain 142, 2722–2736. doi: 10.1093/brain/aww188

Fluiter, K., Oppermann, A. L., Morgan, B. P., Baas, F., and Ramaglia, V. (2014). Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J. Immunol. 192, 2339–2348. doi: 10.4049/jimmunol.1302793

Fonseca, M. I., Chu, S.-H., Vincenten, M. C. J., et al. (2020). Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. Brain 143, 1714–1730. doi: 10.1093/brain/awaa117
Fraser, D. A., Psalypatou, K., and Tenner, A. J. (2010). C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. J. Neurochem. 112, 733–743. doi: 10.1111/j.1471-4159.2009.06494.x

Frischer, J. M., Bramow, S., Dal-Bianco, A., Luccinetti, C. F., Rauschka, H., Schmidbaur, H., et al. (2009). The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175–1189. doi: 10.1093/brain/awp070

Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., et al. (2015). Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann. Neurol. 78, 710–721. doi: 10.1002/ana.24497

Fu, H., Liu, B., Frost, J. L., Hong, S., Jin, M., Ostaszewski, B., et al. (2012). Detection of altered hippocampal morphology in multiple sclerosis disease state. J. Neuroimmunol. 241, 124–127. doi: 10.1016/j.jneuroim.2010.03.014

Ingram, G., Loveless, S. E., Howell, O. W., Hakobyan, S., Dancey, B., Harris, C. L., et al. (2014). Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol. Commun. 2:53. doi: 10.1186/2051-5960-2-53

Györfi, B. A., Kun, J., Torók, G., Bulyéki, E., Borhegyi, Z., Gulyássy, P., et al. (2018). Local apoptotic-like mechanisms underlie complement-mediated synaptic pruning. Proc. Natl. Acad. Sci. U S A 115, 6303–6308. doi: 10.1073/pnas.1722613115

Haidar, L., Fischer, M. T., Frischer, J. M., Bauer, J., Hofbinger, R., Botond, G., et al. (2011). Oxidative damage in multiple sclerosis lesions. Brain 134, 1914–1924. doi: 10.1093/brain/awr128

Haidar, L., Zrzavy, T., Hametner, S., Hofbinger, R., Bagnato, F., Grabner, G., et al. (2016). The topography of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 139, 807–815. doi: 10.1093/brain/awr398

Hajishengallis, G., Reis, E. S., Mastellos, D. C., Ricklin, D., and Lambris, J. D. (2017). Novel mechanisms and functions of complement. Nat. Immunol. 18, 1288–1298. doi: 10.1038/ni.3858

Hammond, J. W., Bellizzi, M. J., Ware, C., Qiu, W. Q., Saminathan, P., Li, H., et al. (2020). Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain Behav. Immun. 87, 739–750. doi: 10.1016/j.bbi.2020.03.004

Harrison, D. M., Roy, S., Oh, J., Izbudak, I., Pham, D., Courtney, S., et al. (2015). Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis. JAMA Neurol. 72, 1004–1012. doi: 10.1001/jamaneurol.2015.1241

Henderson, A. P., Barnett, M. H., Parratt, J. D., and Prineas, J. W. (2009). Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 66, 759–753. doi: 10.1002/ana.21800

Hsu, S., Beja-Glasser, V. F., Wonoynim, B. M., Frouin, A., Li, S., Ramakrishnan, S., et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712–716. doi: 10.1126/science.aad8573

Hou, M., Liu, J., Liu, F., Liu, K., and Yu, B. (2014). C1q tumor necrosis factor-related protein-3 protects mesencymal stem cells against hypoxia- and deprivation-induced apoptosis through the phosphoinositide 3-kinase/Akt pathway. Int. J. Mol. Med. 33, 97–104. doi: 10.3892/ijmm.2013.1550

Howell, G. R., Macalinao, D. G., Sousa, G. L., Walden, M., Soto, I., Kneeland, S. C., et al. (2011). Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J. Clin. Invest. 121, 1429–1444. doi: 10.1172/JCI44646

Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., et al. (2011). Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755–2771. doi: 10.1093/brain/awr182

Howell, O. W., Schulz-Trieglaff, E. K., Carassiti, D., Genteman, S. M., Nicholas, R., Roncaroli, F., et al. (2015). Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathol. Appl. Neurobiol. 41, 798–813. doi: 10.1111/nan.12199

Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., et al. (2006). Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682–687. doi: 10.1038/nm1419

Ighani, M., Jonas, S., Izbudak, I., Choi, S., Lema-Dopico, A., Hua, J., et al. (2020). No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis. Mult. Scler. 26, 165–176. doi: 10.1177/1352458519876037

Ingram, G., HakoByan, S., Hirst, C. L., Harris, C. L., Loveless, S., Mitchell, J. P., et al. (2012). Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult. Scler. 18, 1401–1411. doi: 10.1177/1352458512438238

Ingram, G., HakoByan, S., Hirst, C. L., Harris, C. L., Pickersgill, T. P., Cosburn, M. D., et al. (2010a). Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133, 1602–1611. doi: 10.1093/brain/awq085

Ingram, G., HakoByan, S., Robertson, N. P., and Morgan, B. P. (2010b). Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J. Neuroimmunol. 223, 124–127. doi: 10.1016/j.jneuroim.2010.03.014

Ingram, G., HakoByan, S., Robertson, N. P., and Morgan, B. P. (2009). Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin. Exp. Immunol. 155, 128–139. doi: 10.1111/j.1365-2249.2008.03830.x

Ingram, G., Loveless, S., Howell, O. W., HakoByan, S., Danacey, B., Harris, C. L., et al. (2014). Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol. Commun. 2:53. doi: 10.1186/2051-5960-2-53

Gray, E., Thomas, T. L., Betrouni, S., Scolding, N., and Love, S. (2008). Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol. 18, 86–95. doi: 10.1111/j.1525-3639.2007.01101.x

Gold, S. M., O’Connor, M. F., Montag, M. F., Kim, J. M., Kim, A., Yoo, Y. S., et al. (2010). Smaller cormn ammonia 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol. Psychiatry 68, 553–559. doi: 10.1016/j.biopsych.2010.04.025

Gold, S. M., O’Connor, M. F., Gill, R., Kern, K. C., Shi, Y., Henry, R. G., et al. (2014). Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum. Brain Mapp. 35, 30–37. doi: 10.1002/hbm.22154

Gray, E., Thomas, T. L., Betrouni, S., Scolding, N., and Love, S. (2008). Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol. 18, 86–95. doi: 10.1111/j.1525-3639.2007.01101.x
International Multiple Sclerosis Genetics Consortium. (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science* 365:eaav7188. doi: 10.1126/science.aav7188

Jackson, S. J., Lee, J., Nikodemova, M., Fabry, Z., and Duncan, I. D. (2009). Quantification of myelin and axon pathology during relapsing-remitting experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. *J. Neuropathol. Exp. Neurol.*, 68, 616–625. doi: 10.1097/NEN.0b013e318141d123

Jans, H., Heltberg, A., Zeeberg, I., Kristensen, J. H., Fog, T., and Raun, N. E. (1984). Immunological and blood-brain barrier dysfunction. *Haematologica*, 69, 34–38. doi: 10.1111/j.1600-0404.1984.tb07777.x

Jongen, P. J., Doesburg, W. H., Ibrahim-Stappers, J. L., Lemmens, W. A., Hommes, O. R., and Lamers, K. J. (2000). Cerebrospinal fluid C3 and C4 indexes in neurological disorders of the central nervous system. *Acta Neurol. Scand.*, 101, 116–121. doi: 10.1034/j.1600-0404.2000.10010211.x

Joseph, F. G., Hirst, C. L., Pickersgill, T. P., Ben-Shlomo, Y., Robertson, N. P., and Scolding, N. J. (2009). CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. *J. Neurol. Neurosurg. Psychiatry* 80, 292–296. doi: 10.1136/jnnp.2008.158096

Kaczorowski, S. L., Schilding, J. K., Toth, C. A., and Kochanek, P. M. (1995). Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. *J. Cereb. Blood Flow Metab.*, 15, 860–864. doi: 10.1093/jcbfm/15.6.860

Karadottir, R., Cavelier, P., Berghers, L. H., and Attwell, D. (2005). NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. *Nature*, 438, 1162–1166. doi: 10.1038/nature04302

Kaskow, B. J., and Baecher-Allan, C. (2018). Effector T cells in multiple sclerosis. *Cold Spring Harb. Perspect. Med.* 8:a029025. doi: 10.1101/hsperpectives.a029025

Kebir, H., Kreybomg, I., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Kaczorowski, S. L., Schiding, J. K., Toth, C. A., and Kochanek, P. M. (1995). The immunogenesis of the multiple sclerosis plaque. *Acta Neuropathol.*, 101, 116–121. doi: 10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q

Kooi, E. J., Geurts, J. J., van Horssen, J., Bo, L., and van der Valk, P. (2019). Microglia in the chronic active stage of multiple sclerosis: an overview. *Brain Pathol.* 29, 210–218. doi: 10.1111/bpa.12546

Kool, P. G., Kolev, M., Liszewski, M. K., Kolev, M., Le Friec, G., Leung, M., Bertram, P. G., Fara, A. F., et al. (2013). Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. *Immunity*, 39, 1143–1157. doi: 10.1016/j.immuni.2013.10.018

Liu, J. S., Zhao, M. L., Broman, C. F., and Lee, S. C. (2001). Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. *Am. J. Pathol.*, 158, 2057–2066. doi: 10.1002/ajpath.11667-9

Longoni, G., Roca, M. A., Pagani, E., Riccittelli, G. C., Colombo, B., Rodegher, M., et al. (2015). Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS. *Brain Struct. Funct.* 220, 435–444. doi: 10.1007/s00429-013-0665-9

Loveless, S., Neal, J. W., Howell, O. W., Harding, K. E., Sarkies, P., Evans, R., et al. (2018). Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. *Brain Pathol.*, 28, 507–520. doi: 10.1111/bpa.12546

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sorenson, P. S., Thompson, A. J., et al. (2014). Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*, 83, 278–286. doi: 10.1212/WNL.0000000000000560

Luccinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M., and Lassmann, H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. *Ann. Neurol.*, 47, 707–717. doi: 10.1002/1531-8249(200006)47:6<707::aid-ana5>3.0.co;2-q

Luccinetti, C. F., Popescu, B. F., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., et al. (2011). Inflammatoric cortical demyelination in early multiple sclerosis. *N. Engl. J. Med.*, 365, 2188–2197. doi: 10.1056/NEJMoa1100648

Lui, H., Zhang, J., Maksinon, S. R., Cahill, M. K., Kelley, K. W., Huang, H. Y., et al. (2016). Programmed cell death promotes circuit-specific synaptic pruning by microglia via complement activation. *Cell* 165, 921–935. doi: 10.1016/j.cell.2016.04.001

Lumsden, C. E. (1971). The immunogenesis of the multiple sclerosis plaque. *Brain Res.*, 28, 365–390. doi: 10.1016/S0006-8993(71)90052-7

Macaron, G., and Ontaneda, D. (2019). Diagnosis and management of progressive multiple sclerosis. *Biomedicines*, 7, 56. doi: 10.3390/biomedicines7030056

Machado-Santos, J., Saij, E., Troscher, A. R., Paunovic, M., Lliblau, R., Gabriely, G., et al. (2018). The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. *Brain*, 141, 2066–2082. doi: 10.1093/brain/awy151

Magliozzi, R., Hametner, S., Facchiano, F., Marastoni, D., Rossi, S., Castellaro, M., et al. (2019). Iron homeostasis, complement and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. *Ann. Clin. Transl. Neurol.*, 6, 2150–2163. doi: 10.1002/acn2.50893

Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., et al. (2007). Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain* 130, 1089–1104. doi: 10.1093/brain/awm638
Morgan et al. Complement in the MS Brain

Magliozzi, R., Howell, O. W., Nicholas, R., Cruciani, C., Castellaro, M., Romualdi, C., et al. (2018). Inflammatory intralesional profiles and cortical damage in multiple sclerosis. Ann. Neurol. 83, 739–755. doi: 10.1002/ana.25197

Magliozzi, R., Howell, O. W., Reeves, C., Roncaroli, F., Nicholas, R., Serafini, B., et al. (2010). A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 68, 477–493. doi: 10.1002/ana.22230

Mabod, D. J., Ziaabrea, I., Campbell, G., Lax, N., White, K., Hanson, P. S., et al. (2009). Mitochondrial changes within axons in multiple sclerosis. Brain 132, 1161–1174. doi: 10.1093/brain/awp046

Maier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., and Lemere, C. A. (2008). Complement C3 deficiency leads to accelerated amyloid β plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28, 6333–6341. doi: 10.1523/JNEUROSCI.0829-08.2008

Mallucci, G. R. (2009). Prion neurodegeneration: starts and stops at the synapse. Prion 3, 195–201. doi: 10.4161/prion.3.4.9981

Marik, C., Felts, P. A., Bauer, J., Lassmann, H., and Smith, K. J. (2007). Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130, 2800–2815. doi: 10.1093/brain/awm236

Markiewski, M. M., Nilsson, B., Ekdahl, K. N., Molines, T. E., and Lambris, J. D. (2007). Complement and coagulation: strangers or partners in crime? Trends Immunol. 28, 184–192. doi: 10.1016/j.it.2007.02.006

Martin, M., and Blom, A. M. (2016). Complement in removal of the dead—balancing inflammation. Immunol. Rev. 274, 218–232. doi: 10.1111/imr.12462

Martinez-Forero, I., Garcia-Munoz, R., Martinez-Pasamar, S., Inoges, S., Lopez-Diaz de Cerio, A., Palacios, R., et al. (2008). IL-10 suppressor activity and ex vivo Trl1 cell function are impaired in multiple sclerosis. Eur. J. Immunol. 38, 576–586. doi: 10.1002/eji.200737271

Martinez Sosa, S., and Smith, K. J. (2007). Understanding a role for hypoxia in vivo leukocytes early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury. J. Neuroinflammation 5:26. doi: 10.1186/1742-2094-5-26

Nishimoto, H., Yamamoto, A., Furukawa, S., Wakisaka, S., and Maeda, T. (2017). C1q/TNF-related protein 3 expression and effects on adipocyte differentiation of 3T3-L1 cells. Cell Biol. Int. 41, 197–203. doi: 10.1002/cbin.10674

Okazawa, H., Motegi, S., Ohyama, N., Ohnishi, H., Tomizawa, T., Kaneko, Y., et al. (2005). Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J. Immunol. 174, 2004–2011. doi: 10.4042/jimmunol.174.4.2004

Oldendorp, P. A., Gresham, H. D., and Lindberg, F. P. (2001). CD47-signal regulatory protein α (SIRPα) regulates Fcy and complement receptor-mediated phagocytosis. J. Exp. Med. 193, 855–862. doi: 10.1084/jem.193.7.855

Oldendorp, P. A., Zheleznyak, A., Fang, Y. F., Lagenaur, C. F., Gresham, H. D., and Lindberg, F. P. (2000). Role of CD47 as a marker of self on red blood cells. Science 288, 2051–2054. doi: 10.1126/science.288.5473.2051

Papadopoulos, D., Dukes, S., Patel, R., Nicholas, R., Vora, A., and Reynolds, R. (2009). Substantial archaeocorticalatrophy and neuronal loss in multiple sclerosis. Brain Pathol. 19, 238–253. doi: 10.1111/j.1750-3639.2008.00177.x

Pasinetti, G. M., Johnson, S. A., Rozovsky, I., Lampert-Etchells, M., Morgan, D. G., Gordon, M. N., et al. (1992). Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp. Neurol. 118, 117–125. doi: 10.1016/0014-4886(92)90028-o

Petersen, P. Y. (1976). Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed. Proc. 35, 2428–2434.

Peterson, J. W., Bo, L., Mork, S., Chang, A., and Trapp, B. D. (2001). Transected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389–400. doi: 10.1002/ana.1123

Pikor, N. B., Astarita, J. L., Summers-Deluca, L., Galica, G., Qu, J., Ward, L. A., et al. (2015). Integration of Th17- and lymphotaxon-derived signals initiates meningeal-resident stromal cell remodeling to propagate neuroinflammation. Immunity 43, 1160–1173. doi: 10.1016/j.immuni.2015.11.010

Popescu, B. F., Bunyan, R. F., Parisi, J. E., Ransohoff, R. M., and Lucinetti, C. F. (2011). A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology 76, 1705–1710. doi: 10.1212/WNL.0b013e31821a4401

Prineas, J. W., Kwon, E. E., Cho, E. S., Sharer, L. R., Barnett, M. H., Oleszak, E. L., et al. (2001). Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 50, 646–657. doi: 10.1002/ana.1255

Qiao, F., Atkinson, C., Kindy, M. S., Shunmugavel, A., Morgan, B. P., Song, H., et al. (2010). The alternative and terminal pathways of complement mediated post-traumatic spinal cord inflammation and injury. Am. J. Pathol. 177, 3061–3070. doi: 10.2353/ajpath.2010.100158

Qiao, F., Atkinson, C., Song, H., Pannu, R., Singh, I., and Tomlinson, S. (2006). Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am. J. Pathol. 169, 1039–1047. doi: 10.1016/j.ajpath.2006.060248

Ramaglia, V., Florescu, A., Zuo, M., Sheikh-Mohamed, S., and Gommerman, J. L. (in press a). Stromal cell-mediated coordination of immune cell recruitment, retention, and function in brain-adjacent regions. J. Immunol. 206.

Ramaglia, V., Rojas, O., Naour, I., and Gommerman, J. L. (in press b). The Ins and outs of central nervous system inflammation—lessons learned from multiple sclerosis. Ann. Rev. Immunol. 39.

Ramaglia, V., Hughes, T. R., Donev, R. M., Ruseva, M. M., Wu, X., Huttinga, I., et al. (2012). C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc. Natl. Acad. Sci. U S A 109, 965–970. doi: 10.1073/pnas.1111924109

Ramaglia, V., Jackson, S. J., Hughes, T. R., Neal, J. W., Baker, D., and Morgan, B. P. (2015). Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clin. Exp. Immunol. 180, 432–441. doi: 10.1111/cei.12595

Ramaglia, V., King, R. H., Morgan, B. P., and Baas, F. (2009a). Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Mol. Immunol. 46, 1892–1896. doi: 10.1016/j.molimm.2009.01.017

Ramaglia, V., King, R. H., Nourallah, M., Wolterman, R., de Jonge, R., Ramkema, M., et al. (2007). The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J. Neurosci. 27, 7663–7672. doi: 10.1523/JNEUROSCI.5623-06.2007
Morgan et al. Complement in the MS Brain

Ramaglia, V., Sheikh-Mohamed, S., Legg, K., Park, C., Rojas, O. L., Zandee, S., et al. (2019). Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. *eLife* 8:e48051. doi: 10.7554/eLife.48051

Ramaglia, V., Tannemaat, M. R., de Kok, M., Wolterman, R., Vigar, M. A., King, R. H., et al. (2009b). Complement inhibition accelerates regeneration in a model of peripheral nerve injury. *Mol. Immunol.* 47, 302–309. doi: 10.1016/j.molimm.2009.09.019

Ramaglia, V., Wolterman, R., de Kok, M., Vigar, M. A., Wagenaar-Bos, I., King, R. H., et al. (2008). Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury. *Am. J. Pathol.* 172, 1043–1052. doi: 10.2353/apath.2008.070660

Reali, C., Magliozzi, R., Roncaroli, F., Nicholas, R., Howell, O. W., and Reynolds, R. (2020). B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. *Brain Pathol.* 30, 779–793. doi: 10.1111/bpa.12841

Reinhold, M. I., Lindberg, F. P., Plas, D., Reynolds, S., Peters, M. G., and McGeer, P. L. (2002). Complement activated C4d immunoreactive lesions by mass cytometry. *Neurology* 59, 1357–1368. doi: 10.1167/iovs.05-0865

Rosthøjner, R., Ramirez, M., Cole, G. J., Mueller, K., and Rogers, J. (2002). Microarray analysis of retinal gene expression in the DBA/2J model of glaucoma. *Invest. Ophthalmol. Vis. Sci.* 43, 977–985. doi: 10.1167/iovs.05-0865

Stone, L. A., Smith, M. E., Bash, C. N., Maloni, H., Frank, J. A., et al. (1995). Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender and age. *Neurology* 45, 1122–1126. doi: 10.1212/wnl.45.6.1122

Storch, M. K., Puddlesden, S., Halita, M., livanainen, M., Morgan, P., and Lassmann, H. (1998). Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. *Ann. Neurol.* 43, 465–471. doi: 10.1002/ana.410430409

Strohmeyer, R., Ramirez, M., Cole, G. J., Mueller, K., and Rogers, J. (2002). Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer’s disease brain. *J. Neuroimmunol.* 131, 135–146. doi: 10.1016/s0165-5728(02)00272-2

Svensson, M., and Alldskogius, H. (1992). Evidence for activation of the complement cascade in the hypoglossal nucleus following peripheral nerve injury. *J. Neuroimmunol.* 40, 99–109. doi: 10.1016/0165-5728(92)90217-9

Sewell, D. L., Nacewicz, B., Liu, F., Macvilay, S., Erdei, A., Lambris, J. D., et al. (2019). Multiplexed imaging of immune cells in staged multiple sclerosis. *Brain Pathol.* 30, 217–230. doi: 10.1111/bpa.12841

Trachtenberg, J. T., Chen, B. E., Knott, G. W., Feng, G., Sanes, J. R., and Trapp, B. D. (2004). Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. *Nature* 420, 788–794. doi: 10.1038/nature01273

Trapp, B. D., Peterson, J., Rasnoff, R. M., Rudick, R., Mork, S., and Bo, L. (1998). Axonal transection in the lesions of multiple sclerosis. *N. Engl. J. Med.* 338, 278–285. doi: 10.1056/NEJM19980129338052
Complement in the MS Brain

Wang, C., Yue, H., Hu, Z., Shen, Y., Ma, J., Li, J., et al. (2020). Microglia.

Ward, L. A., Lee, D. S., Sharma, A., Wang, A., Naouar, I., Ma, X. I., et al. (2018). Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science 359, 1269–1273. doi: 10.1126/science.aal3589

van Horssen, J., Brink, B. P., de Vries, H. E., van der Valk, P., and Bo, L. (2007). The blood-brain barrier in cortical multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 66, 321–328. doi: 10.1097/nen.0b013e318040b2de

Vasek, M. J., Garber, C., Dorsey, D., Durrant, D. M., Bollman, B., Soung, A., et al. (2008). Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123, 79–89. doi: 10.1083/immunet.2007.020809x

Vigillette, V., Beecher-Allan, C., Weiner, H. L., and Hafler, D. A. (2004). Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971–979. doi: 10.1084/jem.20031579

Vladimirova, O., O’Connor, J., Cahill, A., Alder, H., Butunoi, C., and Kalman, B. (1998). Oxidative damage to DNA in plaques of MS brains. Mult. Scler. 4, 413–418. doi: 10.1177/135245859800400503

Walker, D. G., Kim, S. U., and McGeer, P. L. (1995). Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J. Neurosci. Res. 40, 478–493. doi: 10.1002/jnr.49040407

Wang, C., Yue, H., Hu, Z., Shen, Y., Ma, J., Li, J., et al. (2020). Microglia mediate forgetting via complement-dependent synaptic elimination. Science 367, 688–694. doi: 10.1126/science.aaz2288

Ward, L. A., Lee, D. S., Sharma, A., Wang, A., Naouar, I., Ma, X. I., et al. (2016). Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury. JCI Insight 5:e132522. doi: 10.1172/jci.insight.132522

Watkins, L. M., Neal, J. W., Loveless, S., Michaliddou, I., Ramaglia, V., Rees, M. I., et al. (2016). Complement is activated in progressive multiple sclerosis cortical grey matter lesions. J. Neuroinflammation 13:161. doi: 10.1186/s12974-016-0631-x

Wegner, C., Esiri, M. M., Chance, S. A., Palace, J., and Matthews, P. M. (2006). Neocortical neuronal, synaptic and glial loss in multiple sclerosis. Neurology 67, 960–967. doi: 10.1212/01.wnl.0000237551.26858.39

Werneburg, S., Jung, J., Kunjamma, R. B., Ha, S. K., Luciano, N. J., Willis, C. M., et al. (2020). Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in Demyelinating disease. Immunity 52, 167–172.e7. doi: 10.1016/j.immuni.2019.12.004

Williams, P. A., Tribble, J. R., Pepper, K. W., Cross, S. D., Morgan, B. P., Morgan, J. E., et al. (2016). Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Mol. Neurodegener. 11:26. doi: 10.1186/s13204-016-0091-6

Willis, C. M., Nicaise, A. M., Menoret, A., Ryu, J. K., Mendiola, A. S., Jellison, E. R., et al. (2019). Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis. Proc. Natl. Acad. Sci. U S A 116, 10488–10493. doi: 10.1073/pnas.1816911116

Witte, M. E., Bo, L., Rodenburg, R. J., Behen, J. A., Musters, R., Hazes, T., et al. (2009). Enhanced number and activity of mitochondria in multiple sclerosis lesions. J. Pathol. 219, 193–204. doi: 10.1002/path.2582

Wyss-Coray, T., Yan, F., Lin, A. H., Lambris, J. D., Alexander, J. J., Quigg, R. J., et al. (2002). Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc. Natl. Acad. Sci. U S A 99, 10837–10842. doi: 10.1073/pnas.162350199

Yang, Y., Tian, S. J., Wu, L., Huang, D. H., and Wu, W. P. (2011). Fibrinogen depleting agent batroxobin has a beneficial effect on experimental autoimmune encephalomyelitis. Cell. Mol. Neurobiol. 31, 437–448. doi: 10.1007/s10571-010-9637-2

You, H., Tsotsui, S., Hameed, S., Kannayakal, T. J., Chen, L., Xia, P., et al. (2012). Abeta neurotoxicity depends on interactions between copper ions, prion protein and N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U S A 109, 1737–1742. doi: 10.1073/pnas.1110791109

Zeis, T., Probst, A., Steck, A. J., Stadelmann, C., Bruck, W., and Schaeren-Wiemers, N. (2009). Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol. 19, 459–466. doi: 10.1111/j.1750-3639.2008.00231.x

Zelek, W. M., Fathalla, D., Morgan, A., Touchard, S., Loveless, S., Tallantyre, E., et al. (2019). Cerebrospinal fluid complement system biomarkers in demyelinating disease. Mult. Scler. 26, 1929–1937. doi: 10.1177/135245881985106

Zrzavy, T., Hametner, S., Wimmer, I., Butovisky, O., Weiner, H. L., and Lassmann, H. (2017). Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain 140, 1900–1913. doi: 10.1093/brain/aws113

Zurawski, J., Taudhid, S., Chu, R., Khalid, F., Healy, B. C., Weiner, H. L., et al. (2020). 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult. Scler. 26, 177–187. doi: 10.1177/135245851985106

Conflict of Interest: VR is co-inventor of a patent that describes the use of inhibitors of the terminal complement pathway for therapeutic purposes; she is co-founders of Regenesance B.V. and received consulting honorarium from EMD Serono and Fluidigm. JLG has received funding from Roche, Novartis and EMD Serono for research and funding from Roche for consulting activities. BPM is a consultant for RaPharma.

Copyright © 2021 Morgan, Gommernan and Ramaglia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.